The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call

Tuesday, October 19, 2010

Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call06:30 EDT Tuesday, October 19, 2010ANAHEIM, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the third quarter ended September 30, 2010 on Thursday, October 28, 2010 after the market close. The Company will host a conference call and webcast on Thursday, October 28, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's third quarter results and current corporate developments.  The dial-in number for the conference call is 877-941-7133 for domestic participants and 480-629-9821 for international participants.A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days.  This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4378038#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company with products that help patients with serious, difficult-to-treat medical conditions.  Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is approved for the treatment of exacerbations associated with multiple sclerosis and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Questcor will market Acthar for the treatment of patients with infantile spasms, a rare form of refractory childhood epilepsy.  Acthar is also approved for 15 other indications. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.  For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or investors, Gregory Gin or Doug Sherk, +1-415-896-6820, or media, Janine McCargo, +1-646-688-0425, all of EVC Group for Questcor Pharmaceuticals, Inc.